Biotechs continue to decline like tech stocks but the sector is adequately capitalized, analysts say.

Valuations for biotech stocks have slumped. This in particular opens up great opportunities for mergers and acquisitions.

Valuations for biotech stocks have slumped, but could rebound.

Things may be looking up for biotech stocks, says Real Money's Bret Jensen.

Mark Hulbert explains why the most popular stocks often prove to be disappointing performers.

Scammers are taking advantage of the crypto craze to line their pockets, FTC says.

Sky-high home prices are driving younger buyers out of the market.

The CEO of Tesla has become one of the most influential voices in the world.

Roblox's shares are down 71% since January.